The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
K. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
M. Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
S. Siena
Consultant or Advisory Role - AstraZeneca; Merck Serono; Roche
E. Van Cutsem
Research Funding - Amgen
J. Huang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. Humblet
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
J. Van Laethem
No relevant relationships to disclose
T. Andre
Honoraria - Amgen
J. S. Wiezorek
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen